Bezafibrate Reduces Elevated Hepatic Fumarate in Insulin-Deficient Mice

Bezafibrate Reduces Elevated Hepatic Fumarate in Insulin-Deficient Mice

Glucotoxic metabolites and pathways play a crucial role in diabetic complications, and new treatment options which improve glucotoxicity are highly warranted. In this study, we analyzed bezafibrate (BEZ) treated, streptozotocin (STZ) injected mice, which showed an improved glucose metabolism compare...

Full description

Bibliographic Details
Main Authors: Andras Franko, Martin Irmler, Cornelia Prehn, Silke S. Heinzmann, Philippe Schmitt-Kopplin, Jerzy Adamski, Johannes Beckers, Jürgen-Christoph von Kleist-Retzow, Rudolf Wiesner, Hans-Ulrich Häring, Martin Heni, Andreas L. Birkenfeld, Martin Hrabě de Angelis
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Biomedicines
Subjects:
bezafibrate
diabetes
fumarate
insulin resistance
lysophosphatidylcholine
Online Access:https://www.mdpi.com/2227-9059/10/3/616

Internet

https://www.mdpi.com/2227-9059/10/3/616

Similar Items